Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 537954, 8 pages
http://dx.doi.org/10.1155/2015/537954
Clinical Study

Treatment of β-Thalassemia/Hemoglobin E with Antioxidant Cocktails Results in Decreased Oxidative Stress, Increased Hemoglobin Concentration, and Improvement of the Hypercoagulable State

1Department of Biochemistry, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
2Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand
3Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
4Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Received 3 March 2015; Revised 22 April 2015; Accepted 30 April 2015

Academic Editor: Daniela Giustarini

Copyright © 2015 Orn-uma Yanpanitch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. J. Weatherall, “Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias,” Nature Reviews Genetics, vol. 2, no. 4, pp. 245–255, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Rund and E. Rachmilewitz, “β-thalassemia,” The New England Journal of Medicine, vol. 353, no. 11, pp. 1135–1146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Opartkiattikul, Y. Funahara, A. Hijikata-Okunomiya, N. Yamaguchi, S. Fucharoen, and P. Talalak, “Detection of PF3 availability in whole blood from volunteers and beta-thalassemia/HbE patients: a promising method for prediction of thrombotic tendency,” The Southeast Asian Journal of Tropical Medicine and Public Health, vol. 23, supplement 2, pp. 52–59, 1992. View at Google Scholar · View at Scopus
  4. B. R. Lentz, “Exposure of platelet membrane phosphatidylserine regulates blood coagulation,” Progress in Lipid Research, vol. 42, no. 5, pp. 423–438, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. K. M. Musallam, M. D. Cappellini, and A. T. Taher, “Iron overload in β-thalassemia intermedia: an emerging concern,” Current Opinion in Hematology, vol. 20, no. 3, pp. 187–192, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Breuer, C. Hershko, and Z. I. Cabantchik, “The importance of non-transferrin bound iron in disorders of iron metabolism,” Transfusion Science, vol. 23, no. 3, pp. 185–192, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Brissot, M. Ropert, C. Le Lan, and O. Loréal, “Non-transferrin bound iron: a key role in iron overload and iron toxicity,” Biochimica et Biophysica Acta: General Subjects, vol. 1820, no. 3, pp. 403–410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Kruszewski, “The role of labile iron pool in cardiovascular diseases,” Acta Biochimica Polonica, vol. 51, no. 2, pp. 471–480, 2004. View at Google Scholar · View at Scopus
  9. R. W. Kalpravidh, N. Siritanaratkul, P. Insain et al., “Improvement in oxidative stress and antioxidant parameters in β-thalassemia/Hb E patients treated with curcuminoids,” Clinical Biochemistry, vol. 43, no. 4-5, pp. 424–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. S. Elalfy, A. A. M. Adly, A. A. M. Attia, F. A. Ibrahim, A. S. Mohammed, and A. M. Sayed, “Effect of antioxidant therapy on hepatic fibrosis and liver iron concentrations in β-thalassemia major patients,” Hemoglobin, vol. 37, no. 3, pp. 257–276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Gharagozloo, B. Moayedi, M. Zakerinia et al., “Combined therapy of silymarin and desferrioxamine in patients with β-thalassemia major: a randomized double-blind clinical trial,” Fundamental and Clinical Pharmacology, vol. 23, no. 3, pp. 359–365, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. W. Kalpravidh, A. Wichit, N. Siritanaratkul, and S. Fucharoen, “Effect of coenzyme Q10 as an antioxidant in β-thalassemia/Hb E patients,” BioFactors, vol. 25, no. 1–4, pp. 225–234, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. A. El-Beshlawy, C. Manz, M. Naja et al., “Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience,” Annals of Hematology, vol. 87, no. 7, pp. 545–550, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Pennell, V. Berdoukas, M. Karagiorga et al., “Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis,” Blood, vol. 107, no. 9, pp. 3738–3744, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. Hashemian, A. Hashemi, and M. Fateminasab, “The benefits of vitamin E on liver function and the hemopoietic system in thalassemia patients,” Iranian Journal of Pediatric Hematology and Oncology, vol. 2, no. 4, pp. 153–158, 2012. View at Google Scholar
  16. W. P. Pfeifer, G. R. Degasperi, M. T. Almeida, A. E. Vercesi, F. F. Costa, and S. T. O. Saad, “Vitamin E supplementation reduces oxidative stress in beta thalassaemia intermedia,” Acta Haematologica, vol. 120, no. 4, pp. 225–231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Tesoriere, D. D'Arpa, D. Butera et al., “Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in β-thalassemia intermedia patients,” Free Radical Research, vol. 34, no. 5, pp. 529–540, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Amer, D. Atlas, and E. Fibach, “N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells,” Biochimica et Biophysica Acta: General Subjects, vol. 1780, no. 2, pp. 249–255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Singh, R. C. Hider, and J. B. Porter, “A direct method for quantification of non-transferrin-bound iron,” Analytical Biochemistry, vol. 186, no. 2, pp. 320–323, 1990. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Brandt and A. S. Keston, “Synthesis of diacetyldichlorofluorescin: a stable reagent for fluorometric analysis,” Analytical Biochemistry, vol. 11, no. 1, pp. 6–9, 1965. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Stocks and T. L. Dormandy, “The autoxidation of human red cell lipids induced by hydrogen peroxide,” British Journal of Haematology, vol. 20, no. 1, pp. 95–111, 1971. View at Publisher · View at Google Scholar · View at Scopus
  22. C. C. Winterbourn, R. E. Hawkins, M. Brian, and R. W. Carrell, “The estimation of red cell superoxide dismutase activity,” Journal of Laboratory and Clinical Medicine, vol. 85, no. 2, pp. 337–341, 1975. View at Google Scholar · View at Scopus
  23. E. Beutler, Red Cell Metabolism: A Manual of Biochemical Methods, Grune & Stratton, London, UK, 3rd edition, 1984.
  24. O. W. Griffith, “Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine,” Analytical Biochemistry, vol. 106, no. 1, pp. 207–212, 1980. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Lamchiagdhase, C. Rattanapong, S. Lerdwana, R. Nitipongwanich, E. Noulsri, and K. Pattanapanyasat, “Red blood cell vesicles in thalassemia,” Journal of the Medical Association of Thailand, vol. 87, no. 3, pp. 233–238, 2004. View at Google Scholar · View at Scopus
  26. J. Graff, U. Klinkhardt, S. Harder et al., “Immunosuppressive therapy regimen and platelet activation in renal transplant patients,” Clinical Pharmacology & Therapeutics, vol. 72, no. 4, pp. 411–418, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. A. R. Cohen, R. Galanello, A. Piga, A. DiPalma, C. Vullo, and F. Tricta, “Safety profile of the oral iron chelator deferiprone: a multicentre study,” British Journal of Haematology, vol. 108, no. 2, pp. 305–312, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. V. Viprakasit, I. Nuchprayoon, A. Chuansumrit et al., “Deferiprone (GPO-L-ONE) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand,” The American Journal of Hematology, vol. 88, no. 4, pp. 251–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Pootrakul, P. Sirankapracha, J. Sankote et al., “Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand,” British Journal of Haematology, vol. 122, no. 2, pp. 305–310, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Chakraborty and M. Bhattacharyya, “Antioxidant defense status of red blood cells of patients with β-thalassemia and Eβ-thalassemia,” Clinica Chimica Acta, vol. 305, no. 1-2, pp. 123–129, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. R. W. Kalpravidh, T. Tangjaidee, S. Hatairaktham et al., “Glutathione redox system in β-Thalassemia/Hb E patients,” The Scientific World Journal, vol. 2013, Article ID 543973, 7 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. Q. Ma and A. Y. H. Lu, “Pharmacogenetics, pharmacogenomics, and individualized medicine,” Pharmacological Reviews, vol. 63, no. 2, pp. 437–459, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Berdoukas, K. Farmaki, S. Carson, J. Wood, and T. Coates, “Treating thalassemia major-related iron overload: the role of deferiprone,” Journal of Blood Medicine, vol. 3, pp. 119–129, 2012. View at Publisher · View at Google Scholar
  34. Y. Jiao, J. Wilkinson IV, X. Di et al., “Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator,” Blood, vol. 113, no. 2, pp. 462–469, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Pootrakul, W. Breuer, M. Sametband, P. Sirankapracha, C. Hershko, and Z. I. Cabantchik, “Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator,” Blood, vol. 104, no. 5, pp. 1504–1510, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Jiao, J. Wilkinson IV, E. C. Pietsch et al., “Iron chelation in the biological activity of curcumin,” Free Radical Biology and Medicine, vol. 40, no. 7, pp. 1152–1160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. F. Atroshi, A. Rizzo, T. Westermarck, and T. Ali-Vehmas, “Antioxidant nutrients and mycotoxins,” Toxicology, vol. 180, no. 2, pp. 151–167, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Kitaoka, G. Liu, N. Masuoka, K. Yamashita, M. Manabe, and H. Kodama, “Effect of sulfur amino acids on stimulus-induced superoxide generation and translocation of p47phox and p67phox to cell membrane in human neutrophils and the scavenging of free radical,” Clinica Chimica Acta, vol. 353, no. 1-2, pp. 109–116, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. I. Rahman and W. MacNee, “Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches,” Free Radical Biology and Medicine, vol. 28, no. 9, pp. 1405–1420, 2000. View at Publisher · View at Google Scholar · View at Scopus
  40. J.-S. Lee and Y.-J. Surh, “Nrf2 as a novel molecular target for chemoprevention,” Cancer Letters, vol. 224, no. 2, pp. 171–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. R. F. A. Zwaal and A. J. Schroit, “Pathophysiologic implications of membrane phospholipid asymmetry in blood cells,” Blood, vol. 89, no. 4, pp. 1121–1132, 1997. View at Google Scholar · View at Scopus
  42. J.-E. Kim, M. Han, K.-S. Hanl, and H. K. Kim, “Vitamin e inhibition on platelet procoagulant activity: involvement of aminophospholipid translocase activity,” Thrombosis Research, vol. 127, no. 5, pp. 435–442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. M. G. Traber, “How much vitamin E? ... Just enough!,” The American Journal of Clinical Nutrition, vol. 84, no. 5, pp. 959–960, 2006. View at Google Scholar · View at Scopus
  44. K. Pattanapanyasat, S. Gonwong, P. Chaichompoo et al., “Activated platelet-derived microparticles in thalassaemia,” British Journal of Haematology, vol. 136, no. 3, pp. 462–471, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Ruf, M. Pick, V. Deutsch et al., “In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with β-thalassaemia major,” British Journal of Haematology, vol. 98, no. 1, pp. 51–56, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. B. H. Shah, Z. Nawaz, S. A. Pertani et al., “Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling,” Biochemical Pharmacology, vol. 58, no. 7, pp. 1167–1172, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Steiner, “Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease,” Nutrition Reviews, vol. 57, no. 10, pp. 306–309, 1999. View at Google Scholar · View at Scopus
  48. M. C. Berndt and R. K. Andrews, “Thrombotic thrombocytopenic purpura: reducing the risk?” The Journal of Clinical Investigation, vol. 121, no. 2, pp. 522–524, 2011. View at Publisher · View at Google Scholar · View at Scopus